Alector, Inc. (NASDAQ:ALEC) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Alector, Inc. (NASDAQ:ALEC) have been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $4.00.

ALEC has been the subject of several recent research reports. HC Wainwright raised their target price on shares of Alector from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Morgan Stanley reiterated an “underweight” rating and set a $1.50 price objective (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th.

Alector Stock Performance

Alector stock opened at $1.27 on Tuesday. The business’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.92. The company has a market cap of $126.99 million, a PE ratio of -0.75 and a beta of 0.76. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $6.78.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The firm had revenue of $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. As a group, analysts predict that Alector will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in shares of Alector by 71.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock valued at $28,000 after acquiring an additional 6,096 shares during the period. ProShare Advisors LLC boosted its position in Alector by 30.3% during the fourth quarter. ProShare Advisors LLC now owns 27,367 shares of the company’s stock worth $52,000 after purchasing an additional 6,367 shares in the last quarter. SG Americas Securities LLC grew its holdings in Alector by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock valued at $74,000 after purchasing an additional 8,581 shares during the period. Geode Capital Management LLC grew its holdings in Alector by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company’s stock valued at $3,619,000 after purchasing an additional 10,308 shares during the period. Finally, Invesco Ltd. increased its position in shares of Alector by 27.7% in the fourth quarter. Invesco Ltd. now owns 47,985 shares of the company’s stock valued at $91,000 after buying an additional 10,405 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.